BioSpace News Archive

Bausch Health Companies Inc., Bausch + Lomb, a leading global eye health business, and Nicox, an international ophthalmology company, announced that VYZULTA®, 0.024%, has received regulatory approval in Ukraine, bringing the total number of countries where VYZULTA is approved to market to seven.

Eagle Pharmaceuticals, Inc. announced that its Board of Directors has approved a $25 million accelerated share repurchase transaction with JPMorgan Chase Bank, National Association as part of the Company’s existing $160 million share repurchase program.

NovaBay® Pharmaceuticals, Inc. announces expanded Avenova® consumer marketing programs designed to generate greater awareness of its antimicrobial lid and lash spray and promote online sales.

Telix Pharmaceuticals Limited announces it has submitted a New Drug Application to the United States Food and Drug Administration for TLX591-CDx, a radiopharmaceutical targeting Prostate-Specific Membrane Antigen for the imaging of prostate cancer using Positron Emission Tomography.1

John M. Gay, Vice President, Finance and Corporate Controller with over 20 years of financial and accounting experience appointed as Chief Financial Officer

Amicus Therapeutics announced the European Medicines Agency has granted Priority Medicines designation to AT-GTX-501, the Company’s investigational gene therapy for children living with variant late infantile neuronal ceroid lipofuscinosis 6 disease, also known as CLN6 Batten disease.

CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced the launch of AlloCare at the CareDx organized AlloCare Transplant Festival on September 26, 2020.

IncellDx, Inc., a global leader in single-cell diagnostics, announces the USPTO has issued patent US10,782,298 to IncellDx.

Gunze Limited [TOKYO:3002] is pleased to announce that Gunze’s biodegradable scaffolds are being provided to the Abigail Wexner Research Institute at Nationwide Children’s Hospital to conduct its first human tissue engineered vascular grafts, clinical trial.

According to the report, the global pelvic floor electrical stimulation devices market was valued at US$ 300 Mn in 2019 and is projected to expand at a CAGR of 9.5% from 2020 to 2030.